Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial OfficerGlobeNewsWire • 02/23/26
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech SummitGlobeNewsWire • 02/03/26
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% PremiumGlobeNewsWire • 01/13/26
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026GlobeNewsWire • 01/10/26
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewsWire • 11/25/25
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?Zacks Investment Research • 11/19/25
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/05/25
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate UpdateGlobeNewsWire • 11/05/25
Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs TranscriptSeeking Alpha • 10/31/25
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader ProgramsGlobeNewsWire • 10/30/25
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity SummitGlobeNewsWire • 10/16/25
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should KnowZacks Investment Research • 09/01/25
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences CompaniesPRNewsWire • 08/28/25
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom FishingZacks Investment Research • 08/08/25
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/05/25
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate UpdateGlobeNewsWire • 08/05/25
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/14/25
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateGlobeNewsWire • 05/14/25
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsGlobeNewsWire • 05/01/25
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateGlobeNewsWire • 04/28/25